Holen Sie sich die Stockscreener-App
2.21
8.11%
-0.195
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
Will ALX Oncology Holdings Inc. stock pay special dividends2025 EndofYear Setup & Safe Investment Capital Preservation Plans - mfd.ru
Why ALX Oncology Holdings Inc. stock could outperform in 2025M&A Rumor & Reliable Entry Point Alerts - mfd.ru
Will ALX Oncology Holdings Inc. stock benefit from upcoming earnings reports2025 Risk Factors & Weekly High Momentum Picks - mfd.ru
Will ALX Oncology Holdings Inc. outperform tech stocksGDP Growth & Expert Verified Stock Movement Alerts - mfd.ru
Will ALX Oncology Holdings Inc. stock hit new highs in YEARQuarterly Trade Review & Breakout Confirmation Alerts - mfd.ru
Meme Stocks: Can ALX Oncology Holdings Inc reach all time highs this yearJuly 2025 Spike Watch & Reliable Breakout Forecasts - baoquankhu1.vn
Is ALX Oncology Holdings Inc. a stock for growth or value investorsTrade Volume Report & Free Technical Pattern Based Buy Signals - mfd.ru
ALX Oncology announces pricing of underwritten offering; shares up nearly 15% - MSN
3 Promising Penny Stocks With Market Caps Over $100M - Yahoo Finance
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Institutional Investor Builds Significant Stake in ALX Oncology - AD HOC NEWS
ALXO: Analyst Raises Price Target to $4.00, Maintains Overweight Rating | ALXO Stock News - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ALX Oncology (ALXO) Rises on Significant Share Purchase by venBi - GuruFocus
ALX Oncology Shares Surge 10% After Major VC Purchase - Intellectia AI
Wilson Sonsini Advises ALX Oncology on Public Offering - Wilson Sonsini
CD47 Protein May Predict Evorpacept Success in Metastatic Breast Cancer - Cure Today
ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants - Nasdaq
ALX Oncology prices $150 million stock offering at $1.57 per share - Investing.com Nigeria
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer - Investing News Network
ALX Oncology reports CD47 biomarker findings in breast cancer trial By Investing.com - Investing.com Nigeria
ALXO Unveils Promising Data from Evorpacept Trial in Breast Canc - GuruFocus
ALX Oncology announces major underwritten public equity offering - TipRanks
ALX Oncology Announces Pricing of Underwritten Offering - The Manila Times
ALX Oncology reports CD47 biomarker findings in breast cancer trial - Investing.com
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - The Manila Times
ALX Oncology Holdings Inc Announces New Clinical Trial Data - TradingView
What is ALX Oncology Holdings Inc.’s book value per shareTrade Exit Report & Daily Chart Pattern Signals - mfd.ru
Can ALX Oncology Holdings Inc. reach all time highs this yearDip Buying & Daily Volume Surge Trade Alerts - mfd.ru
IPO Launch: Is ALX Oncology Holdings Inc affected by consumer sentimentPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
VIX Spike: Is ALX Oncology Holdings Inc in accumulation or distribution phase2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn
Investment Report: Will ALX Oncology Holdings Inc stock hit new highs in YEARIPO Watch & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ALX Oncology increases shares reserved for inducement equity plan By Investing.com - Investing.com Nigeria
ALX Oncology increases shares reserved for inducement equity plan - Investing.com
ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks
Aug Volume: How does QuantumScape Corporation correlate with NasdaqEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Downgrade Watch: Is Teledyne Technologies Incorporated a cyclical or defensive stockMarket Rally & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Highs Report: Does ALX Oncology Holdings Inc. have high return on assetsJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - bollywoodhelpline.com
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference - MarketBeat
ALX Oncology : Investor Presentation ALX presentation at JPM 2026 12Jan2026 FINAL (698186) - marketscreener.com
Aug Spikes: Will ALX Oncology Holdings Inc stock recover after earnings - baoquankhu1.vn
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks - Yahoo Finance
Stock Report: Why ALX Oncology Holdings Inc stock remains undervaluedPortfolio Performance Summary & AI Enhanced Trading Alerts - Bộ Nội Vụ
Is ALX Oncology Holdings Inc. stock trading near support levelsJuly 2025 Fed Impact & Weekly Top Performers Watchlists - Улправда
Hedge Fund Moves: How geopolitical tensions affect ALX Oncology Holdings Inc. stockJuly 2025 Update & Consistent Profit Trading Strategies - Улправда
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Why ALX Oncology Holdings Inc. stock remains undervaluedWeekly Market Report & Daily Momentum Trading Reports - Улправда
How ALX Oncology Holdings Inc. stock compares to market leadersJuly 2025 Momentum & Safe Capital Growth Stock Tips - Улправда
How geopolitical tensions affect ALX Oncology Holdings Inc. stock2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
ALX Oncology Advances Separate Clinical Trials Evaluating - GlobeNewswire
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Meme Stocks: Will ALX Oncology Holdings Inc stock deliver consistent dividends2025 Valuation Update & Weekly Market Pulse Updates - moha.gov.vn
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):